Brokerages Expect Alaunos Therapeutics, Inc. (NASDAQ:TCRT) to Announce -$0.09 Earnings Per Share

Equities analysts predict that Alaunos Therapeutics, Inc. (NASDAQ:TCRTGet Rating) will post earnings per share of ($0.09) for the current quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Alaunos Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.05) and the lowest estimate coming in at ($0.13). Alaunos Therapeutics reported earnings of ($0.11) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 18.2%. The firm is scheduled to issue its next earnings results on Monday, January 1st.

On average, analysts expect that Alaunos Therapeutics will report full year earnings of ($0.32) per share for the current financial year, with EPS estimates ranging from ($0.40) to ($0.22). For the next fiscal year, analysts forecast that the company will post earnings of ($0.33) per share, with EPS estimates ranging from ($0.37) to ($0.30). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side analysts that follow Alaunos Therapeutics.

Alaunos Therapeutics (NASDAQ:TCRTGet Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.05) earnings per share for the quarter, hitting the consensus estimate of ($0.05).

Several research firms recently issued reports on TCRT. HC Wainwright reiterated a “neutral” rating on shares of Alaunos Therapeutics in a report on Thursday, March 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alaunos Therapeutics in a report on Monday, May 9th. Wells Fargo & Company upgraded Alaunos Therapeutics from an “equal weight” rating to an “overweight” rating and set a $3.00 target price on the stock in a report on Wednesday, May 4th. Raymond James set a $2.00 target price on Alaunos Therapeutics and gave the stock a “market perform” rating in a report on Friday, April 1st. Finally, Zacks Investment Research upgraded Alaunos Therapeutics from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a report on Wednesday, May 4th. Two analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $1.83.

Shares of TCRT stock traded up $0.01 on Thursday, hitting $0.51. 27,009 shares of the stock were exchanged, compared to its average volume of 2,864,661. The company has a debt-to-equity ratio of 0.28, a current ratio of 4.91 and a quick ratio of 4.91. The stock has a market cap of $109.38 million, a price-to-earnings ratio of -1.32 and a beta of 1.58. The business has a 50-day moving average of $0.58. Alaunos Therapeutics has a fifty-two week low of $0.41 and a fifty-two week high of $3.73.

About Alaunos Therapeutics (Get Rating)

Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors.

Recommended Stories

Get a free copy of the Zacks research report on Alaunos Therapeutics (TCRT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with's FREE daily email newsletter.